Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PDXK | O00764 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31150926 | 1.00 | NOS2 (0.45) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL27964282 | 0.82 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL3679899 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10MAOA | |
| SCHEMBL23857046 | 0.80 | NOS2 (0.44) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL463497 | 0.79 | NOS2 (0.63) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL7052034 | 0.78 | NOS2 (0.68) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL31150936 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10MAOA | |
| SCHEMBL1565183 | 0.78 | NOS2 (0.42) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL21352029 | 0.78 | KDM4E (0.37) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL23857355 | 0.78 | KDM4E (0.37) | NOS2NOS3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688753-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| US-20260028327-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2024211686-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
| US-5726172-A | BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA | MERCK & CO., INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997025992-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | NOS2 2464/4885NOS3 2690/4885KDM4E 3899/4885 |
| US-20260028327-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN1, KCNC1, HCN2 | NOS2 3645/4885NOS3 2719/4885KDM4E 3406/4885 |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CCR2, CXCR2, CCR1 | NOS2 2847/4885NOS3 3260/4885KDM4E 4539/4885 |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | NOS2 3832/4885NOS3 2918/4885KDM4E 3650/4885 |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | NOS2 4721/4885NOS3 4645/4885KDM4E 139/4885 |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, PNLIP | NOS2 2907/4885NOS3 2499/4885KDM4E 4749/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | NOS2 2464/4885NOS3 2690/4885KDM4E 3899/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | NOS2 4592/4885NOS3 2959/4885KDM4E 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.